In rotary tablet compression suites handling a botanical veterinary API, incoming Zhuangyang Powder is first passed through a conical mill fitted with a 0.8 mm rasp screen to break soft agglomerates before charging into a 500 L bin blender. A pre-blend of 25.0% w/w Zhuangyang Powder and 1.0% w/w croscarmellose sodium is dispersed into a lactose monohydrate and microcrystalline cellulose diluent system to achieve a target dose of 250 mg per 1 g tablet; low-dose variants containing 50–100 mg per tablet use 8.0–15.0% w/w API with geometric dilution. Blend uniformity is sampled from 10 locations using a unit-dose thief and assayed by HPLC validated according to VICH GL1 and VICH GL2. The granulation step is performed in a top-spray fluid-bed granulator with inlet air temperature 55–65°C, binder spray rate 60–120 g/min, and 5.0% w/w PVP K30 solution until granules reach a moisture endpoint of 2.5–3.0% by loss on drying. After drying, the granules are dry-milled and lubricated with 0.75% w/w magnesium stearate for not more than 5 min in a V-blender at 20 rpm; prolonged lubrication produces a hydrophobic coating that reduces tablet hardness and slows disintegration below the USP <701> limit of 15 min for uncoated tablets. Compression is performed on a 16-station rotary tablet press at 30–50 rpm turret speed, applying 8–15 kN main compression force to achieve hardness of 60–100 N and friability not more than 1.0% according to USP <1216>. Finished tablets are tested for content uniformity per USP <905>, weight variation, and dissolution by USP <711> Apparatus 2 in 0.1 N hydrochloric acid at 50 rpm, with acceptance criteria set by the approved regulatory method. Terminal product types include 250 mg, 500 mg, and 1000 mg uncoated or film-coated oral tablets intended for swine, cattle, and equine use, packaged in HDPE bottles with desiccant canisters. Industry compliance references include FDA 21 CFR Part 211, EU GMP Annex 11 for computerized blending controls, and VICH GL1/GL2 for analytical method validation. A critical operational boundary is that the botanical powder must be pre-dried at 45°C for 4 h when ambient RH exceeds 60%; failure to control moisture leads to sticking and picking during compaction at high turret speeds.

What Changes When the Same API Is Transferred to a Terminal-Sterilized Injection?

Injectable manufacturing imposes different constraints because botanical APIs carry an insoluble particulate load and variable bioburden. The downstream process begins with dissolution or suspension of Zhuangyang Powder in Water for Injection preheated to 70–80°C; if the active fraction is heat-labile, dissolution is limited to 40–50°C and sterilization is shifted to membrane filtration. The addition ratio for a 50 mg/mL injectable solution is 5.0% w/v, adjusted by assay potency; for 100 mg/mL formulations the ratio is 10.0% w/v and may require a propylene glycol co-solvent system at 10–20% v/v when solubility is insufficient. The solution is clarified through a depth filter followed by 0.45 µm and 0.22 µm polyethersulfone membrane filters; transmembrane pressure should not exceed 1.0 bar, and filter area for a 100 L batch is typically 0.6 m² to prevent filter fouling from residual insoluble cell matrix. Terminal sterilization by autoclave at 121°C for 15 min requires an F0 value ≥ 12 for heat-stable formulations; heat-labile formulations use aseptic filtration in an ISO 14644-1 Class 5 environment. Particulate matter is controlled to USP <788> limits: not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container for large-volume parenterals, or the harmonized Ph. Eur. 2.9.19 limits for small-volume products. Bacterial endotoxin is tested per USP <85> and Ph. Eur. 2.6.14, with a use-based limit commonly set at 0.5 EU/mg for parenteral products, though the final limit must be justified from dose, route, and target species. Terminal products include 50 mL and 100 mL multi-dose vials, single-dose ampoules, and lyophilized powder for reconstitution where aqueous instability is confirmed by accelerated stability studies per VICH GL3. A documented incompatibility is that the solution should not be combined with strongly alkaline buffers above pH 8.0 or with amine-based preservatives if polyphenolic constituents are present, because precipitate formation and assay loss have been observed in pilot-scale batches; published data for this specific configuration is limited beyond these operational observations.

Hard capsule operations using dosator or tamping-pin filling machinery place strict limits on the powder’s flow function coefficient. Zhuangyang Powder is pre-blended with lactose monohydrate, pregelatinized starch, and 0.5% w/w colloidal silicon dioxide to achieve a bulk density of 0.45–0.60 g/mL and a Carr index ≤ 25. The formulation addition ratio is typically 20–35% w/w of the finished capsule fill, with the exact proportion determined by target dose and the assay of the incoming API lot. Blend lubrication uses 0.25% w/w sodium stearyl fumarate rather than magnesium stearate to reduce sensitivity to over-lubrication in low-fill-weight capsules. The final blend is sealed in HDPE drums and held for 2 h before filling. Encapsulation is performed on a fully automatic machine operating at up to 150,000 capsules/hour at 40–50% RH and 18–22°C; empty capsule shells must be conditioned to 12–15% moisture to prevent brittleness. Capsule weight variation is controlled to USP <905> limits for the initial 10 units, and dissolution is performed according to USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N hydrochloric acid, with a Q value of 75% at 45 min where specified by the approved regulatory method for immediate-release products. Terminal product types include size 1 and size 0 hard gelatin capsules and vegetarian HPMC capsules containing 125 mg, 250 mg, or 500 mg Zhuangyang Powder per unit, packaged in PVC/aluminum blisters or HDPE bottles. The applicable compliance standards are FDA 21 CFR 211, USP <905> for uniformity, USP <711> for dissolution, and VICH GL4 for stability. A processing boundary is that direct-fill formulations with excessive fines below 75 µm generate dust and inconsistent fill weights, so particle size distribution must be monitored by sieve analysis per USP <811>.

Soluble Powder for Drinking Water: In-Line Dosing and Hard Water Precipitation

Mass medication through drinking water subjects the API to a specific set of dissolution, stability, and dosing accuracy constraints. Zhuangyang Powder is blended with anhydrous dextrose and 0.5–1.0% w/w citric acid buffer in a 500 kg ribbon mixer to form a water-soluble powder; the addition ratio is 5.0% w/w in the concentrated water-soluble powder, designed to deliver a stock solution concentration of 1.0–2.0 g/L through a 1–5% proportioner pump. The blend is milled through an air classifier mill to a D90 ≤ 75 µm to reduce settling and nozzle clogging; residual moisture after milling is kept below 2.0% by loss on drying. Packaging in aluminum-lined foil bags under nitrogen is required when stability trials indicate oxidative degradation above 25°C. Downstream process controls include in-line conductivity measurement before and after mixing to confirm complete dissolution, and periodic sampling of the stock solution for assay. Hard water with total hardness above 300 mg/L as CaCO₃ may cause precipitation of poorly soluble mineral complexes; if precipitation is observed, the use of a chelating agent such as EDTA at 0.1–0.3% w/w or acidification to pH 5.5–6.5 is recommended. Terminal product types include 100 g, 500 g, and 1 kg water-soluble powder sachets for poultry and swine, and reconstituted medicated stock solutions for proportioner systems. Compliance references include EU 2019/4 for medicated feed and water, FDA 21 CFR 558 for medicated feed additives where a regulatory approval exists, and VICH GL18 for residual solvents in the blended powder. Published data for this specific configuration is limited regarding the ionic strength threshold for precipitation in bicarbonate-rich well water; therefore, field validation with the actual water source is required.

When Medicated Premix Granules Are Extruded with Wheat Midds and Binder

Extrusion of medicated premix granules shifts the control burden from powder flow to moisture equilibration, binder selection, and thermal stress. The formulation addition ratio in the premix is 2.0–5.0% w/w of Zhuangyang Powder, corresponding to a complete-feed inclusion of 10–20 mg/kg depending on target species and dilution factor. The carrier is a 1:1 mixture of wheat midds and ground corn, with 0.5% w/w calcium lignosulfonate binder and 0.2% w/w propionic acid as mold inhibitor. The dry mix is granulated in a horizontal ploughshare mixer with 8–10% water added at 2 L/min, then extruded through a low-pressure basket extruder fitted with a 1.5 mm screen. Extrudates are spheronized at 500–800 rpm for 2–4 min and dried in a forced-air tray dryer at 50°C until moisture content is 10–12%. Terminal product types are 5 kg and 25 kg multi-wall paper bags of medicated premix granules intended for incorporation into final feed at the mill, and free-choice granular supplements for cattle. Compliance standards for this scenario are FDA 21 CFR 225 for medicated feed manufacturing and EU 2019/4 for carryover control; feed homogeneity is tested by assay of 10 samples per batch and must achieve a coefficient of variation below 5.0%. A process limitation is that extrusion temperatures above 60°C may reduce marker assay in heat-sensitive batches; published data for this specific configuration is limited, therefore thermal mapping of the extruder barrel and post-extrusion assay are mandatory.

In oral drench manufacturing, the API is dispersed in a co-solvent vehicle composed of propylene glycol 20% v/v and purified water 80% v/v, with 0.1% w/v potassium sorbate and 0.05% w/v sodium metabisulfite as antioxidant. The addition ratio is 5.0–10.0% w/v, yielding 50–100 mg/mL of the veterinary API in the final oral solution. The manufacturing process uses a high-shear rotor-stator mixer at 3000 rpm for 15 min to disperse the powder, followed by pH adjustment to 5.5–6.5 with citric acid, and clarification through a 5 µm polypropylene plate and frame filter. Viscosity is controlled at 10–50 mPa·s measured by a Brookfield viscometer at 25°C, and fill weight is checked in 1 L HDPE bottles with induction-sealed caps. Terminal product types include 500 mL and 1 L oral drench bottles, 5 L jerry cans for herd administration, and unit-dose polypropylene syringes for equine use. The compliance framework includes FDA 21 CFR 211 for liquid finished pharmaceuticals, USP <51> for preservative effectiveness, and VICH GL18 for residual solvents. A specific operational boundary is that prolonged high-shear mixing above 30 min can cause foaming and air entrapment, leading to variable fill weights and oxidation; mixing time should therefore be limited and vacuum deaeration applied if foam exceeds 5% of vessel volume.